Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ischemic And Bleeding Risk Assessment After TAVR (FOCUS ONE Registry)

NCT06000943 is registered in ClinicalTrials.gov with Niguarda Hospital as lead sponsor.

NCT NCT06000943
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06000943 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ischemic And Bleeding Risk Assessment After TAVR (FOCUS ONE Registry)
Lead sponsor
Niguarda Hospital
Phase
Observational
Overall status
Recruiting
Start date
August 1, 2023
Completion date
December 15, 2026
Enrollment
2,500 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

aortic valve stenosis, transcatheter aortic valve replacement